Oral Baclofen Has a Limited Role in Spasmodic Torticollis
Oral baclofen is NOT recommended as a primary treatment for spasmodic torticollis (cervical dystonia); botulinum neurotoxin injections are the established first-line therapy and should be offered instead. 1
Why Botulinum Toxin, Not Baclofen
The 2017 AAN guidelines explicitly address cervical dystonia (the medical term for spasmodic torticollis) and establish that all FDA-approved formulations of botulinum neurotoxin are the standard of care, with AboBoNT-A and rimaBoNT-B having the strongest evidence (should be offered), while OnaBoNT-A and incoBoNT-A also demonstrate similar efficacy (should be considered) 1.
Critically, the FDA-approved indications for oral baclofen specifically exclude dystonia. The drug label states baclofen is indicated for spasticity from multiple sclerosis and spinal cord diseases, but explicitly notes: "The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions" 2. Dystonia is conspicuously absent from approved indications.
The Evidence Gap for Baclofen in Dystonia
While a 1992 retrospective study found that high-dose baclofen (40-180 mg daily) provided dramatic improvement in approximately 30% of children and adolescents with idiopathic dystonia, the response in adults with focal dystonia like torticollis was far less impressive 3. One series of 60 adults with cranial dystonia found sustained benefit in only 18%, and smaller series have not consistently demonstrated significant benefit in adults 3.
This stands in stark contrast to the robust evidence for botulinum toxin in cervical dystonia, which has established efficacy across multiple formulations 1.
Safety Concerns That Limit Baclofen's Utility
Even when baclofen shows some effect, adverse events are common and dose-limiting, affecting 25-75% of patients 4. The most problematic side effects include:
- Muscle weakness (particularly concerning in dystonia where you're not trying to reduce all muscle tone)
- Somnolence and sedation
- Nausea
- Paresthesias
The FDA label warns about sedation affecting operation of vehicles and machinery, additive CNS depression with alcohol, and potential worsening of seizure control in epileptic patients 2. Additionally, ovarian cysts occur in approximately 4% of patients on chronic baclofen therapy 2.
Clinical Algorithm
For an adult presenting with spasmodic torticollis:
First-line: Offer botulinum neurotoxin injections (AboBoNT-A or rimaBoNT-B preferred; OnaBoNT-A or incoBoNT-A as alternatives) 1
If botulinum toxin fails or is contraindicated: Consider oral baclofen as a second-line option only, recognizing:
- Response rate in adult focal dystonia is poor (≤18%) 3
- Start low (5-15 mg three times daily) and titrate slowly
- Maximum dose typically 80 mg daily (though some studies used up to 180 mg) 3
- Monitor closely for sedation, weakness, and other CNS effects 2
- Expect that most patients will not achieve adequate benefit
If oral baclofen causes intolerable side effects at subtherapeutic doses: Intrathecal baclofen bypasses the blood-brain barrier and may optimize efficacy while minimizing systemic side effects 4, though this is rarely used for isolated cervical dystonia
Key Pitfall to Avoid
Do not prescribe oral baclofen as initial therapy for spasmodic torticollis simply because it's easier to prescribe than arranging botulinum toxin injections. This delays definitive treatment with an evidence-based therapy and exposes patients to a medication with poor efficacy for their condition and significant side effect burden. The guideline evidence strongly favors botulinum toxin as the appropriate first-line intervention 1.